Live Biotherapeutics as cancer treatments: scientific and regulatory challenges

Staff editor

20.09.2023

Jean-Luc Marsat, CEO & Chairman at EverImmune, discusses the research EverImmune carries out in oncology.

During the Microbiome Connect Europe conference, held early in July in Amsterdam, Microbiomepost sat down with Jean-Luc Marsat, CEO & Chairman at EverImmune, to discuss the research EverImmune carries out in oncology.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Via Podgora 12/A, 20122, Milan, Italy – VAT: IT05299040963

Read MicrobiomePost’s Privacy Policy

This communication is only intended for business-to-business and health care professionals.
This communication is not intended for consumers of final consumer goods.
Nothing on this page is meant to be perceived as an approved claim.

Live Biotherapeutics as cancer treatments: scientific and regulatory challenges

Latest related content

Gut bacteria studied at subspecies level reveal links to colorectal cancer

Gut bacteria cooperate to convert dietary compound into energy, boosting microbial health

Microbiome modulation in menopause: a clinical guide for gynecologists

Microbiota and women’s health: emerging evidence and personalized perspectives

Mice study reveals how drug-resistant bacteria take hold in the gut

Gut microbes may be linked to increased blood clotting and heart disease risk

Latest News